Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab

BACKGROUND: We evaluated antidrug antibody (ADA) development in patients with chronic plaque psoriasis from three clinical trials of tildrakizumab, a humanized anti‐interleukin‐23p19 monoclonal antibody (P05495, reSURFACE 1 and reSURFACE 2). OBJECTIVES: To determine the effects of immunogenicity on...

Descripción completa

Detalles Bibliográficos
Autores principales: Kimball, A.B., Kerbusch, T., van Aarle, F., Kulkarni, P., Li, Q., Blauvelt, A., Papp, K.A., Reich, K., Montgomery, D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6972989/
https://www.ncbi.nlm.nih.gov/pubmed/30916381
http://dx.doi.org/10.1111/bjd.17918

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6972989/
https://www.ncbi.nlm.nih.gov/pubmed/30916381
http://dx.doi.org/10.1111/bjd.17918

Ejemplares similares